EUVIMEDEUVIMED entdecken
Crossref

Optimal size of DNA encapsidated by plant produced human papillomavirus pseudovirions

Ayesha Adams, Megan Hendrikse, Edward P Rybicki, Inga I Hitzeroth

Virology · 2023

DOI: 10.1016/j.virol.2023.02.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Virology, 2023. Verfasst von Ayesha Adams und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, 7701, South Africa. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Oncogene Proteins, Viral, Papillomavirus Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Poliomyelitis Research Foundation, Council for Scientific and Industrial Research, South Africa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human papillomaviruses (HPVs) are known to be the cause of anogenital and oropharyngeal cancers as well as genital and common warts. HPV pseudovirions (PsVs) are synthetic viral particles that are made up of the L1 major and L2 minor HPV capsid proteins and up to 8 Kb of encapsidated pseudogenome dsDNA. HPV PsVs are used to test novel neutralising antibodies elicited by vaccines, for studying the virus life cycle, and potentially for the delivery of therapeutic DNA vaccines. HPV PsVs are typically produced in mammalian cells, however, it has recently been shown that Papillomavirus PsVs can be produced in plants, a potentially safer, cheaper and more easily scalable means of production. We analysed the encapsidation frequencies of pseudogenomes expressing EGFP, ranging in size from 4.8 Kb to 7.8 Kb, by plant-made HPV-35 L1/L2 particles. The smaller pseudogenomes were found to be packaged more efficiently into PsVs as higher concentrations of encapsidated DNA and higher levels of EGFP expression were obtained with the 4.8 Kb pseudogenome, compared to the larger 5.8-7.8 Kb pseudogenomes. Thus, smaller pseudogenomes, of 4.8 Kb, should be used for efficient plant production of HPV-35 PsVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus VaccinesOncogene Proteins, ViralPapillomavirus InfectionsMammalsAlphapapillomavirusDNACapsid ProteinsHuman Papillomavirus VirusesHumansAnimalsPapillomaviridae

Stichwörter der Autor:innen

BiopharmingDNA sizeHPVPlant-madePseudogenomePseudovirionsVaccine

Substanzen

Capsid ProteinsDNAPapillomavirus VaccinesOncogene Proteins, Viral

Autor:innen und Institutionen

  • Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, 7701, South Africa.
  • Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, 7701, South Africa; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch,…
  • Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, 7701, South Africa. Electronic address: Inga.hitzeroth@uct.ac.za.

Förderung

  • Poliomyelitis Research Foundation
  • Council for Scientific and Industrial Research, South Africa

Zitieren

APA

Adams, A., Hendrikse, M., Rybicki, E. P., & Hitzeroth, I. I. (2023). Optimal size of DNA encapsidated by plant produced human papillomavirus pseudovirions. Virology. https://doi.org/10.1016/j.virol.2023.02.003

Vancouver

Adams A, Hendrikse M, Rybicki EP, Hitzeroth II. Optimal size of DNA encapsidated by plant produced human papillomavirus pseudovirions. Virology. 2023. doi:10.1016/j.virol.2023.02.003

BibTeX
@article{Adams2023,
  author = {Adams, Ayesha and Hendrikse, Megan and Rybicki, Edward P and Hitzeroth, Inga I},
  title = {Optimal size of DNA encapsidated by plant produced human papillomavirus pseudovirions},
  journal = {Virology},
  year = {2023},
  doi = {10.1016/j.virol.2023.02.003}
}
Kostenlos starten →